Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more
Pharmaron Beijing Co., Ltd. (PHBBF) - Total Liabilities
Latest total liabilities as of June 2025: $10.33 Billion USD
Based on the latest financial reports, Pharmaron Beijing Co., Ltd. (PHBBF) has total liabilities worth $10.33 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmaron Beijing Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how Pharmaron Beijing Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmaron Beijing Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Pharmaron Beijing Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Parq Arauco
SN:PARAUCO
|
Chile | CL$2.18 Trillion |
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
China | CN¥3.67 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥3.52 Billion |
|
DSFIY
PINK:DSFIY
|
USA | $10.92 Billion |
|
Premium Brands Holdings Corporation
PINK:PRBZF
|
USA | $4.35 Billion |
|
Aurubis AG
PINK:AIAGF
|
USA | $4.49 Billion |
|
Spark New Zealand Ltd
PINK:NZTCF
|
USA | $3.03 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Pharmaron Beijing Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmaron Beijing Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmaron Beijing Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of Pharmaron Beijing Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.70 Billion | -26.70% |
| 2023-12-31 | $13.24 Billion | +37.15% |
| 2022-12-31 | $9.65 Billion | +19.26% |
| 2021-12-31 | $8.09 Billion | +172.06% |
| 2020-12-31 | $2.98 Billion | -- |